ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Atox Bio Announces Exercise by BARDA of Next Option Period for NSTI Treatment americanpharmaceuticalreview
June 20, 2019Atox Bio announced the Biomedical Advanced Research and Development Authority (BARDA) has exercised the next option on a performance-based contract with for the development of Reltecimod in patients with Necrotizing Soft Tissue Infections (NSTI). -
Atox Bio Announces Chief Commercial Officer Appointment americanpharmaceuticalreview
February 18, 2019Atox Bio announced the appointment of Robert Greif as Chief Commercial Officer. In this newly created position, Greif will be responsible for building the commercial organization and pre-commercial activities for Reltecimod....
Pharma Sources Insight January 2025
